Table 25GRADE profiles – opioid analgesics (overall) as monotherapy for neuropathic pain

No. of studiesDesignTreatmentPlaceboMean (SD) at endpoint
[p-value]
LimitationsInconsistencyIndirectnessImprecisionOther considerationsQuality
OTHER REPORTED PAIN OUTCOME: Pain intensity (Scale: VASpi-10cm)
1
(Trama)
(NPcan1)
RCT1818Treatment = 2.9 (NR)
Placebo = 4.3 (NR)
p < 0.001
NNSaSbNLow
1
(Trama)
(PDN2)
RCT6566Treatment = 1.4 (0.1)
Placebo = 2.2 (0.1)
p < 0.001
NNSaSbNLow
OTHER REPORTED PAIN OUTCOME: Pain relief (Scale: NRS 11-point)
1
(Trama)
(Poly3)
RCT3742Treatment = 4.5 (2.7)
Placebo = 6.3 (2.4)
p < 0.001
NNSaSbNLow
No. of studiesDesignTreatmentPlaceboMean change (SD) from baseline
[p-value]
LimitationsInconsistencyIndirectnessImprecisionOther considerationsQuality
OTHER REPORTED PAIN OUTCOME: Pain intensity (Scale: NRSpi 11-point)
1
(Oxyco)
(PDN4)
RCT8277Treatment = −2.6 (2.54)
Placebo = −1.5 (2.19)
p < 0.001
NNSaSbNLow

N = No serious; S = Serious; VS = Very serious

Trama = tramadol; NPcan = neuropathic cancer pain; PDN = painful diabetic neuropathy; Poly = polyneuropathy; Oxyco = oxycodone; NR = Not reported

a

Indirect outcome measure.

b

Total number of events < 300 owing to small study sample.

1
2
3
4

From: 2, How this guideline was developed

Cover of Neuropathic Pain
Neuropathic Pain: The Pharmacological Management of Neuropathic Pain in Adults in Non-Specialist Settings.
NICE Clinical Guidelines, No. 96.
Centre for Clinical Practice at NICE (UK).
Copyright © 2010, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.